Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Daniel Prieto-Alhambra, Senior Clinical Research Fellow at NDORMS has been elected co-chair of the International Society of Pharmacoepidemiology (ISPE) Academic Council.

Dr Daniel Prieto-Alhambra, Senior Clinical Research Fellow at NDORMS has been elected co-chair of the International Society of Pharmacoepidemiology (ISPE) Academic Council.

ISPE is a "non-profit international professional membership organisation dedicated to advancing the health of the public". The organisation aims to provide an open forum for the exchange of scientific information and its members represent the various scientific disciplines involved in the study of the effects of drugs (both risks and benefits) in large populations using observational methods. The Academic Council's mission within ISPE is to represent the academic members of the pharmacoepidemiology community and their interests.

Speaking of his appointment, Dr Prieto-Alhambra says: "ISPE is a growing scientific society with representation from industry, regulators, and academics. I will be honored to co-chair (this year) and prospectively chair (in the coming two years) the academic council, and to therefore represent the interests of academics in such a large international organisation".

Similar stories

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

Professor Chris Buckley has joined the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters “good” macrophage behaviour within the vessel wall.

More effective treatment found for patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

NDORMS researchers honoured in the Recognition Of Distinction Scheme 2021

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.